NASDAQ:COAG Hemab Therapeutics Q1 2026 Earnings Report $41.19 -0.03 (-0.07%) As of 09/18/2026 04:00 PM Eastern ProfileEarnings HistoryForecast Hemab Therapeutics EPS ResultsActual EPS-$23.98Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AHemab Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AHemab Therapeutics Announcement DetailsQuarterQ1 2026Date5/21/2026TimeBefore Market OpensConference Call DateThursday, May 21, 2026Conference Call Time7:00AM ETConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Hemab Therapeutics Earnings HeadlinesHemab Therapeutics Holdings (COAG)September 19 at 2:55 PM | za.investing.comHemab Therapeutics Holdings IncSeptember 18 at 8:26 AM | markets.ft.com“Elon’s nightmare” could fund your retirementMarc Chaikin, the 60 year Wall Street veteran whose Chaikin Money Flow indicator sits on every Bloomberg terminal, says a new micro cluster AI technology could render today's data centers, including Elon Musk's Colossus in Tennessee, obsolete for major breakthroughs. These next generation centers use 99 percent less space, electricity and water, yet Chaikin's research shows they could be more than a trillion times more powerful than the top data center on earth today, potentially cutting AI breakthrough timelines from five years to five days. | Chaikin Analytics (Ad)Hemab Therapeutics Doses First Volunteer in Phase 1 HMB-003 StudySeptember 17 at 12:23 PM | marketscreener.comMHemab Therapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of HMB-003, an Investigational Therapy for the Management of Heavy Menstrual BleedingSeptember 17 at 8:00 AM | globenewswire.comHemab Therapeutics Holdings, Inc. (NASDAQ:COAG) Receives $51.40 Consensus PT from BrokeragesSeptember 11, 2026 | americanbankingnews.comSee More Hemab Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Hemab Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Hemab Therapeutics and other key companies, straight to your email. Email Address About Hemab TherapeuticsHemab Therapeutics (NASDAQ:COAG) is a clinical-stage biotechnology company focused on developing treatments for serious and underserved bleeding disorders. The company aims to create therapies that address limitations of existing approaches, including the need for frequent administration and the challenges associated with complex blood-product-based treatments. Its lead investigational program, HMB-001, is being developed for Glanzmann thrombasthenia, a rare inherited disorder in which platelets do not function properly and can cause severe bleeding. Hemab is also advancing additional research programs intended to address other rare bleeding and platelet disorders. Hemab Therapeutics was founded in 2018 and operates across Denmark and the United States. The company’s development programs are focused on advancing novel biologic medicines through clinical testing and, subject to regulatory approval, toward use in patients with significant unmet medical needs.View Hemab Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles J.B. Hunt's Stock Plunges After Market Misprices Profit WarningLennar’s Earnings Miss May Be Sending a Bigger Warning About U.S. HousingLennar's Q3 Miss Hides a Stronger Operating Story Beneath the Housing SlumpAeluma’s Selloff Could Be Setting Up Its Next Big MoveBraze Beat Expectations—Now 2 SaaS Peers Are in FocusPriced for a Pullback or More Gains? These 3 Stocks Are Testing the LimitsCoreWeave’s Vera Rubin Lead Comes Down to Speed, Power, and Scale Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
